Disc Medicine Announces $62.5 Million Financing Led By Bain Capital Life Sciences To Advance Portfolio Of Novel Hematology Programs
Amount Raised
$62.5 Million
Round Type
Funding Round
WatertownBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Disc Medicine, Inc. (NASDAQ: IRON) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it has entered into a securities purchase agreement with certain investors resulting in an aggregate $62.5 million in gross proceeds through a registered direct offering. The financing was led by Bain Capital Life Sciences, who contributed $50 million, with participation from existing investors, Access Biotechnology and OrbiMed.
Who to call at Disc, and when
A new round usually means Disc is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Disc raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Disc, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Disc raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Disc raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.